Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Bristol Myers Squibb (BMY) shared Phase 1 data for zolacabtagene autoleucel (zola-cel) in MS patients, showing promising results. Separately, BMY expanded its AI collaboration with Tempus (TEM) through 2031. BMY stock is down 2.30%, TEM up 1.54%.

Pathos AI, Bristol Myers Squibb, and Tempus AI partnered to accelerate medical research using AI. Pathos AI will access Tempus AI's patient database for $55M, while Bristol Myers Squibb gains strategic access to the technology. Pathos AI raised $237M to develop its platform and advance drug pipelines, including JSKN016 and a breast cancer program with AstraZeneca.

Tempus AI and Bristol Myers Squibb extended their partnership with a multi-year deal for oncological data and AI platform access. The agreement, running through 2031, includes $137.5 million from Bristol Myers and $55 million from Pathos AI for patient records. Pathos AI is also collaborating with both companies on neurological conditions.

Tempus AI (TEM) and Bristol Myers Squibb (BMY) extended their collaboration with a multi-year agreement. BMY will license Tempus' oncology data through 2031 and access its AI-driven Lens Platform for drug discovery. The deal expands their existing partnership in AI and data-driven oncology research.

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) for a multi-year collaboration to develop AI-driven datasets and capabilities for Alzheimer's and neurological conditions. BMY leads Pathos's Series E financing and gains access to Pathos Foundry. Tempus will provide a de-identified dataset for $55 million over five years. Pathos will use its AI platform to analyze the data and design clinical trials.

Pathos AI has secured a $55M deal with Tempus AI to create a neurological disease dataset. Bristol Myers Squibb (BMY) leads Pathos's Series E funding, gaining access to its AI platform. Pathos will use the dataset to analyze disease biology and inform clinical trials.